The State Administration for Industry and Commerce (SAIC) and other regulators last year opened initial investigations into the companies' Chinese health-care units on suspicion of bribing hospitals in exchange for sales, Bloomberg News reported today.
None of the three companies immediately responded to requests by AFP for comment on Monday.
It is the latest reported example of overseas firms being targeted by Chinese authorities, who have launched wide-ranging probes in sectors ranging from autos to baby milk.
GSK was fined 3.0 billion yuan (USD 480 million) last September after a nearly year-long bribery probe.
More From This Section
China's healthcare sector is widely considered to be riddled with graft, partly the result of an opaque tendering system for drugs. Doctors' low salaries are also a factor.
It was not clear whether full formal investigations would follow the medical device inquiries, Bloomberg News cited sources familiar with the matter as saying, nor did the probes necessarily imply wrongdoing.